THE JAK2V617F POINT MUTATION INCREASES THE OSTEOCLAST FORMING ABILITY OF MONOCYTES IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS AND MAKES THEIR OSTEOCLASTS MORE SUSCEPTIBLE TO JAK2 INHIBITIONEmmanouil Spanoudakis, Ιoannis Kotsianidis, Menelaos Papoutselis et al.|Mediterranean Journal of Hematology and Infectious Diseases|2018Cited by 9
The Role of Adenosine Deaminase Acting on RNA 1 (ADAR1) Enzyme in the Resistance to Hypomethylating AgentsDespoina Dimitriou, Ιoannis Kotsianidis, Elsa Bernard et al.|Blood|2024Cited by 0
The Role of the Adenosinergic Pathway in the Resistance to Hypomethylating AgentsGeorge Vrachiolias, Ιoannis Kotsianidis, Eleftheria Lamprianidou et al.|Blood|2024Cited by 0
PROGNOSIS - PREDICTIVE FACTORS OF RESPONSE TO TREATMENTGeorge Vrachiolias, Ιoannis Kotsianidis, Eleftheria Lamprianidou et al.|Leukemia Research|2025Cited by 0
PLENARY SESSION 08: TREATMENT HIGH RISKDespoina Dimitriou, Ιoannis Kotsianidis, Panagiotis Liakopoulos et al.|Leukemia Research|2025Cited by 0